NEW YORK (GenomeWeb News) – The Foundation for the National Institutes of Health's Biomarkers Consortium today announced the availability of results of a proteomics study using plasma samples from its Alzheimer's Disease Neuroimaging Initiative.
The study results are from the Biomarkers Consortium Project Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-based Biomarkers in Alzheimer's Disease, and is intended to be the first part of multi-phase work to use samples collected by ADNI to qualify multiplex panels in both plasma and cerebrospinal fluid that would be used to diagnose patients with Alzheimer's and to monitor their disease progression.
ADNI is a $60 million public-private partnership launched in 2004 supported by NIH. Drug firms, imaging, and clinical trial management companies, not-for-profit firms and donations from individuals also provide funding for the foundation.
ADNI was originally scheduled to end at the end of the year but was recently renewed through 2015.
The study was carried out by members of academia, industry, and government. A statistical analysis of the results is now being done in conjunction with the release of the data, available here.
In a statement, Holly Soares, director of clinical neuroscience biomarkers at Bristol-Myers Squibb, which led the Biomarkers Consortium Project team, said that she hopes the data will result in a blood-based screening test for the early diagnosis of Alzheimer's.
William Potter, who recently retired as vice president of Translation Neuroscience at Merck Research Laboratories, added "Such immediate dissemination of detailed data should accelerate by several years the meaningful application of proteomics to developing the novel drugs desperately needed for this progressive disease."